iCleanse Announces Collaboration with CIT to Offer Low-Interest Financing on All iCleanse Disinfection Products to Kill COVID

What To Know

  • Com, the leader in UV-C personal device disinfection, announced today that it has joined forces with CIT, a top 50 national bank, to provide low-interest financing on all iCleanse disinfection products to keep customers and staff safe from infectious pathogens.
  • Providing quick and effective disinfection for all types of business to help them remain safe and open is the main objective in iCleanse's mission.

iCleanse www.icleanse.com, the leader in UV-C personal device disinfection, announced today that it has joined forces with CIT, a top 50 national bank, to provide low-interest financing on all iCleanse disinfection products to keep customers and staff safe from infectious pathogens.

This alliance allows iCleanse to better serve its current and future customer base, who may have limited cash flow due to the year-long pandemic, making UV-C disinfection more attainable for small and large businesses alike and keeping businesses open. iCleanse products kill 99.9% of infectious pathogens, such as COVID-19, the common cold, and influenza in as little as 15 seconds.

iCleanse’s Mission: Help Businesses Remain Safe and Open

iCleanse is the leader and only patented solution in chemical-free UV-C disinfection for mobile devices. Providing quick and effective disinfection for all types of business to help them remain safe and open is the main objective in iCleanse’s mission. Applying for financing through CIT is quick and easy, and customers can receive a decision on financing often in less than three minutes.

“Being able to offer our customers an easy financial solution to purchase our products is a no-brainer,” said Chris Allen, CEO of iCleanse. “Ensuring easy and effective disinfection of the items we use daily is one way to reduce the spread of the COVID-19 pandemic.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Reeva FT is offered in a variety of sizes: 2x2 cm, 2x3 cm, 4x4 cm, 4x6 cm, 4x8 cm, and 10x15 cm. Reeva FT is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.
The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy